Dr. Nicole Kallewaard leads the Targeted Therapeutics arm of AstraZeneca’s Microbial Sciences Department, which discovers and develops innovative medicines targeting the microbiome and specific bacterial and viral pathogens. Dr. Kallewaard has led cross-functional teams to progress antibody candidates from early discovery through clinical development and contributed to regulatory submissions of several antibody drugs targeting respiratory syncytia virus and influenza. She has several patents describing novel antiviral biologics and has been a leader in the development of in vivo expressed biologics platforms at AstraZeneca. Dr. Kallewaard earned a BS in Microbiology from Michigan State University, a PhD in Microbiology and Immunology from Vanderbilt University, and did her postdoctoral fellowship at the Children’s Hospital of Philadelphia.